$11.76
0.51% yesterday
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US4884451075
Symbol
ZVRA

KemPharm, Inc. Stock price

$11.76
-1.03 8.05% 1M
+4.04 52.33% 6M
+3.42 41.01% YTD
+4.95 72.69% 1Y
+5.65 92.47% 3Y
+3.58 43.70% 5Y
-242.00 95.37% 10Y
-167.44 93.44% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.06 0.51%
ISIN
US4884451075
Symbol
ZVRA
Industry

Key metrics

Basic
Market capitalization
$614.1m
Enterprise Value
$611.5m
Net debt
positive
Cash
$62.6m
Shares outstanding
54.7m
Valuation (TTM | estimate)
P/E
negative | 12.3
P/S
15.1 | 6.5
EV/Sales
15.1 | 6.4
EV/FCF
negative
P/B
15.0
Financial Health
Equity Ratio
22.3%
Return on Equity
-266.0%
ROCE
-49.3%
ROIC
-104.8%
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$40.6m | $95.2m
EBITDA
$-65.4m | $-10.4m
EBIT
$-71.9m | $-15.7m
Net Income
$-92.0m | $52.2m
Free Cash Flow
$-67.8m
Growth (TTM | estimate)
Revenue
44.9% | 303.0%
EBITDA
-19.6% | 87.1%
EBIT
-25.7% | 82.0%
Net Income
-80.7% | 149.5%
Free Cash Flow
-47.7%
Margin (TTM | estimate)
Gross
84.4%
EBITDA
-161.1% | -10.9%
EBIT
-177.1%
Net
-226.6% | 54.9%
Free Cash Flow
-167.1%
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
9.0%
Employees
67
Rev per Employee
$350.0k
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a KemPharm, Inc. forecast:

Buy
93%
Hold
7%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
41 41
45% 45%
100%
- Direct Costs 6.32 6.32
171% 171%
16%
34 34
139% 139%
84%
- Selling and Administrative Expenses 64 64
74% 74%
159%
- Research and Development Expense 33 33
23% 23%
81%
-65 -65
20% 20%
-161%
- Depreciation and Amortization 6.48 6.48
160% 160%
16%
EBIT (Operating Income) EBIT -72 -72
26% 26%
-177%
Net Profit -92 -92
81% 81%
-227%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
Seeking Alpha
13 minutes ago
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Officer Neil F.
Neutral
GlobeNewsWire
about 5 hours ago
Q2 2025 net revenue of $25.9 million , driven by product net revenue of $21.8 million
Neutral
GlobeNewsWire
9 days ago
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 67
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today